Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7401416 | 0.99 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL525363 | 0.96 | FABP5 (0.49) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL17699252 | 0.93 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL289089 | 0.86 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL525667 | 0.86 | FABP5 (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4601031 | 0.86 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL12987564 | 0.84 | FABP5 (0.44) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL12987541 | 0.84 | FABP5 (0.44) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4601669 | 0.84 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4654507 | 0.83 | CTSL (0.40) | FABP5FABP7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637520-B2 | Conjugation chemistry for catalytic antibody 38C2 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-26 | — | — | US | disclosed |
| US-20230012213-A1 | NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-01-12 | — | — | US | disclosed |
| CN-114846030-A | Novel conjugation chemistry that catalyzes antibody 38C2 | 佛罗里达大学研究基金会公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-111978371-B | Polypeptide derivative and application thereof in field of medicine | 成都诺和晟泰生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-113788877-A | Novel insect kinin analogs and application thereof in aphid control | 中国农业大学 | 2021-12-14 | — | — | CN | disclosed |
| CN-108727468-B | Cyclic peptide, pharmaceutical or cosmetic composition comprising the same, and preparation method thereof | 陈建添 | 2021-12-03 | — | — | CN | disclosed |
| EP-3628677-B1 | METHOD FOR PREPARING A CYCLOPEPTIDE | UNIV NAT TSING HUA (TW) | 2021-11-10 | — | — | EP | disclosed |
| EP-3392262-B1 | CYCLOPEPTIDE, PHARMACEUTICAL OR COSMETIC COMPOSITION COMPRISING THE SAME AND METHOD FOR PREPARING THE SAME | UNIV NAT TSING HUA (TW) | 2021-08-18 | — | — | EP | disclosed |
| US-10851134-B2 | Method for preparing cyclopeptide | NATIONAL TSING HUA UNIVERSITY (TW) | 2020-12-01 | — | — | US | disclosed |
| CN-111978371-A | Polypeptide derivative and application thereof in field of medicine | 成都诺和晟泰生物科技有限公司 | 2020-11-24 | — | — | CN | disclosed |
| WO-2002016407-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-02-28 | — | — | WO | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2001-08-23 | — | — | US | disclosed |
| WO-2001058886-A1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-1028942-A2 | DIPEPTIDE NITRILES | Novartis AG (CH) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024460-A2 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 1999-05-20 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851134-B2 | Method for preparing cyclopeptide | PPIB, PPIA, PPIL1 | FABP5 1058/4885FABP7 2753/4885KMT2A 4765/4885 |
| US-12637520-B2 | Conjugation chemistry for catalytic antibody 38C2 | IGLV6-57, SETD1A, KDM4C | FABP5 4767/4885FABP7 4798/4885KMT2A 5/4885 |
| US-20230012213-A1 | NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 | PTMS, MRPS34, SDC2 | FABP5 4724/4885FABP7 4752/4885KMT2A 26/4885 |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | FABP5 4608/4885FABP7 3446/4885KMT2A 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.